Movement Alert｜InnoCare Pharma Rises 5.07% in Regular Trading, HK Innovative Drug Sector Rallies as ADC Pipeline Advances

Market Focus07-10

On July 10, InnoCare Pharma rose 5.07% in regular trading, trading at HKD 14.06/share, with turnover of approximately HKD 74.04 million.

On the news front, Hong Kong-listed innovative drug stocks rallied broadly, with notable gains across the sector including Remegen and InnoCare rising over 5%, WuXi AppTec and WuXi Biologics gaining over 4%, and Hengrui Medicine climbing over 3%, indicating significant capital inflows into the sector.

At the company level, InnoCare recently announced that its self-developed CDH17-targeting novel ADC drug ICP-B208 completed first patient dosing, officially entering the clinical stage. Based on the company's proprietary ADC technology platform, ICP-B208 is designed to precisely target tumor cells while minimizing off-target effects. Currently, no CDH17-targeted ADC drug has been approved globally, highlighting the pipeline's differentiated competitive advantage.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1159004783?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 11:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159004783","market":"us","top_or_hot":-1,"title":"Movement Alert｜InnoCare Pharma Rises 5.07% in Regular Trading, HK Innovative Drug Sector Rallies as ADC Pipeline Advances","media":"Market Focus","content":"<p><p>On July 10, InnoCare Pharma rose 5.07% in regular trading, trading at HKD 14.06/share, with turnover of approximately HKD 74.04 million.</p><p>On the news front, Hong Kong-listed innovative drug stocks rallied broadly, with notable gains across the sector including Remegen and InnoCare rising over 5%, WuXi AppTec and WuXi Biologics gaining over 4%, and Hengrui Medicine climbing over 3%, indicating significant capital inflows into the sector.</p><p>At the company level, InnoCare recently announced that its self-developed CDH17-targeting novel ADC drug ICP-B208 completed first patient dosing, officially entering the clinical stage. Based on the company's proprietary ADC technology platform, ICP-B208 is designed to precisely target tumor cells while minimizing off-target effects. Currently, no CDH17-targeted ADC drug has been approved globally, highlighting the pipeline's differentiated competitive advantage.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜InnoCare Pharma Rises 5.07% in Regular Trading, HK Innovative Drug Sector Rallies as ADC Pipeline Advances</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜InnoCare Pharma Rises 5.07% in Regular Trading, HK Innovative Drug Sector Rallies as ADC Pipeline Advances\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-10 11:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 10, InnoCare Pharma rose 5.07% in regular trading, trading at HKD 14.06/share, with turnover of approximately HKD 74.04 million.</p><p>On the news front, Hong Kong-listed innovative drug stocks rallied broadly, with notable gains across the sector including Remegen and InnoCare rising over 5%, WuXi AppTec and WuXi Biologics gaining over 4%, and Hengrui Medicine climbing over 3%, indicating significant capital inflows into the sector.</p><p>At the company level, InnoCare recently announced that its self-developed CDH17-targeting novel ADC drug ICP-B208 completed first patient dosing, officially entering the clinical stage. Based on the company's proprietary ADC technology platform, ICP-B208 is designed to precisely target tumor cells while minimizing off-target effects. Currently, no CDH17-targeted ADC drug has been approved globally, highlighting the pipeline's differentiated competitive advantage.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09969","symbol_name":"诺诚健华","start_time":0,"source_url":"","article_id":"1159004783","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159004783","pubTimestamp":1783653506,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 10, InnoCare Pharma rose 5.07% in regular trading, trading at HKD 14.06/share, with turnover of approximately HKD 74.04 million.On the news front, Hong Kong-listed innovative drug stocks...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09969":"诺诚健华"},"translate_title":"走势提醒|诺诚健华常规交易上涨5.07%，香港创新药板块因ADC管道推进而反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09969":1},"content_text":"On July 10, InnoCare Pharma rose 5.07% in regular trading, trading at HKD 14.06/share, with turnover of approximately HKD 74.04 million.On the news front, Hong Kong-listed innovative drug stocks rallied broadly, with notable gains across the sector including Remegen and InnoCare rising over 5%, WuXi AppTec and WuXi Biologics gaining over 4%, and Hengrui Medicine climbing over 3%, indicating significant capital inflows into the sector.At the company level, InnoCare recently announced that its self-developed CDH17-targeting novel ADC drug ICP-B208 completed first patient dosing, officially entering the clinical stage. Based on the company's proprietary ADC technology platform, ICP-B208 is designed to precisely target tumor cells while minimizing off-target effects. Currently, no CDH17-targeted ADC drug has been approved globally, highlighting the pipeline's differentiated competitive advantage.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1159004783","isCrawlerRequest":true}